Ortho Regenerative Technologies (CSE:ORTH) Inc said the United States Patent and Trademark Office (USPTO) has issued a patent related to the company's ORTHO-R soft tissue repair platform.
The patent, titled ‘Freeze-Dried Polymer Compositions for mixing with platelet rich plasma to form implants for tissue repair and/or composition for therapeutic intra-articular injection’, provides broad protection for both the composition and the method of use of its Ortho-R Technology, the company said.
"This US patent is a critical step in protecting our technology platform in the world's largest orthopedic soft tissue repair market and provides further validation of our novel and unique approach to soft tissue repair regenerative technologies,” CEO Philippe Deschamps said in a statement.
READ: Ortho Regenerative Technologies closes oversubscribed non-brokered private placement for $3.2M
“Receiving this patent from the USPTO is a key, hard-fought, value creation milestone for the company. This important patent is added to our growing intellectual property portfolio and the nine other patents already issued in major markets around the world," he added.
Ortho Regenerative is a clinical-stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies to dramatically improve the success rate of orthopedic and sports medicine surgeries.
ORTHO-R, its lead Chitosan-PRP hybrid drug/biologic implant combination product, is formulated and designed to increase the healing rates of occupational and sports-related injuries to tendons, meniscus and ligaments.
Ortho said it continues to assess new therapeutic target uses outside of the soft tissue repair field.
Contact the author at jon.hopkins@proactiveinvestors.com